Abstract # 16:

Scheduled for Thursday, August 17, 2006 10:45 AM-11:00 AM: Session 2 (Regency East #2) Oral Presentation

Use of Biomarkers to Predict Disease in Captive Chimpanzees (Pan troglodytes)

D. R. Lee and J. J. Ely
Alamogordo Primate Facility, PO Box 956, Building 1303 , Holloman AFB, NM 88330, USA
     Post-genomics medicine increasingly involves biochemical markers (biomarkers) as prognostic indicators prior to overt clinical disease. We are using a panel of 177 biomarkers to assess current and predict future health status in a colony of 230 chimpanzees (Pan troglodytes), for autoimmune, cardiovascular and infectious diseases. The panel is composed of 78 antigen, 43 autoimmune and 56 infectious disease markers (including hormones, cytokines, chemokines, acute phase reactants, tissue remodeling factors and other blood components), using predominantly sandwich ELISA techniques. Given the predominant role of clinical heart disease in both morbidity (42%) and mortality (57%) at our colony, markers of interest include C-reactive protein (CRP) and complete lipid profile (total cholesterol, LDL, HDL, triglycerides). Animals were classified by disease status (infectious and heart) and sex, with the covarariate, age. Analyses of variance indicated no sex difference for any biomarker (P>0.05). Age effects were present for total cholesterol and Triglycerides (P<0.05). There were significant effects of disease status for total cholesterol, HDL and LDL (P<0.05) but not triglycerides or CRP. Our current results confirm the importance of these biomarkers as prognostic indicators of disease in chimpanzees. Further data and analyses will be presented in more detail, including multivariate analyses of larger subsets of the complete biomarkers panel to elucidate these complex health problems in chimpanzee clinical medicine.